Puma Biotechnology
PBYI
9.60
-0.22
-2.19%
Puma Biotechnology
US · PBYI
#3745 by market cap
9.60
-0.22
-2.19%
Live - 5344 symbols - heartbeat 285s ago
· 2026-10-08 09:58
Pre-market
9.68
-1.33%
After-hours
9.81
0.00%
- Market cap
- 495.29M
- P/E (TTM)i
- 18.81
- P/Bi
- 3.57
- EPSi
- 0.61
- Div yieldi
- 0.00%
- 52W posi
- 91%
Reader sentiment
Are you bullish or bearish on PBYI?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 1 in the most recent period (2026/Q3).
- Total institutional ownership fell 1.2 percentage points.
Institutional ownership
- Held by institutions
- 75.48% -1.22pp
- Institutions
- 194 +1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund56.76%
Individual/Insider15.18%
VC/PE Fund8.00%
Hedge Fund7.38%
Government Pension Fund1.32%
Public Company1.03%
Private Company0.47%
Family Office/Trust0.32%
Insurance Company0.11%
Other9.42%
Top holders as of 2026-07-06
Alan Auerbach
13.74% · 7.09M sh
Acorn Bioventures
8.00% · 4.13M sh
BlackRock
7.37% · 3.80M sh
American Century Investment Management
4.49% · 2.32M sh
Vanguard Capital Management, LLC
4.08% · 2.10M sh
Acadian Asset Management LLC
3.98% · 2.05M sh
Renaissance Technologies Corp.
3.56% · 1.84M sh
Vanguard Portfolio Management, LLC
3.54% · 1.83M sh
LSV Asset Management
3.13% · 1.62M sh
Dimensional Fund Advisors
2.94% · 1.52M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 13 buys · 37 sells
| Name | Role | Stake |
|---|---|---|
| Alan Auerbach | Founder, Chairman, President, CEO & Secretary | 13.74% |
| Maximo Nougues | Chief Financial Officer | 0.35% |
| Douglas Hunt | Senior Vice President of Regulatory Affairs, Pharmacovigilance, Medical Affairs & Law | 0.29% |
| Jeffrey Ludwig | Chief Commercial Officer | 0.18% |
| Brian Stuglik | Independent Director | 0.17% |
| Allison Dorval | Independent Director | 0.12% |
| Michael Miller | Independent Director | 0.10% |
| Jay Moyes | Lead Independent Director | 0.06% |
| Alessandra Cesano | Director | 0.06% |
| Troy Wilson | Independent Director | 0.05% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-13 | Troy Wilson | Independent Director | Open Market Disposition | -5,000 | $9.10 |
| 2026-09-13 | Alessandra Cesano | Director | Open Market Disposition | -12,150 | $9.12 |
| 2026-09-13 | Alessandra Cesano | Director | Derivative Exercise and Sale | -50,000 | $2.93–9.12 |
| 2026-07-05 | Alan Auerbach | Founder, Chairman, President, CEO & Secretary | Automatic Disposition | -44,058 | $8.26 |
| 2026-07-05 | Douglas Hunt | Senior Vice President of Regulatory Affairs, Pharmacovigilance, Medical Affairs & Law | Automatic Disposition | -8,460 | $8.26 |
| 2026-07-05 | Maximo Nougues | Chief Financial Officer | Automatic Disposition | -9,386 | $8.26 |
| 2026-06-11 | Jay Moyes | Lead Independent Director | Automatic Disposition | -22,000 | $7.22 |
| 2026-06-11 | Troy Wilson | Independent Director | Automatic Disposition | -10,800 | $7.20 |
| 2026-06-11 | Adrian Senderowicz | Independent Director | Automatic Disposition | -27,000 | $7.20 |
| 2026-06-11 | Allison Dorval | Independent Director | Automatic Disposition | -11,610 | $7.20 |
| 2026-06-11 | Brian Stuglik | Independent Director | Automatic Disposition | -8,100 | $7.20 |
| 2026-06-10 | Jay Moyes | Lead Independent Director | Other Acquisition | +27,000 | -- |
| 2026-06-10 | Michael Miller | Independent Director | Other Acquisition | +27,000 | -- |
| 2026-06-10 | Troy Wilson | Independent Director | Other Acquisition | +27,000 | -- |
| 2026-06-10 | Alessandra Cesano | Director | Other Acquisition | +27,000 | -- |
| 2026-06-10 | Adrian Senderowicz | Independent Director | Other Acquisition | +27,000 | -- |
| 2026-06-10 | Allison Dorval | Independent Director | Other Acquisition | +27,000 | -- |
| 2026-06-10 | Brian Stuglik | Independent Director | Other Acquisition | +27,000 | -- |
| 2026-02-17 | Alan Auerbach | Founder, Chairman, President, CEO & Secretary | Other Acquisition | +159,778 | -- |
| 2026-02-17 | Alan Auerbach | Founder, Chairman, President, CEO & Secretary | Other Derivative Acquisition | +227,474 | $6.68 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 09:58:52 · For reference only, not investment advice and not tailored to your situation.